Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Index funds often deliver steady returns due to broad diversification and low costs; learn how this supports long-term growth.
24,979 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Nvidia announces a breakthrough that isn’t a chip, signaling a new era for AI infrastructure. Investors react as data...
Nasdaq’s CFO argues that AI is a leadership issue, not a back-office project. With 650 institutions using its AI-powe...
A diversified cybersecurity ETF now holds CrowdStrike alongside 30 other rivals, offering broad exposure as AI-driven...
Marvell Technology has surged in 2026 as AI infrastructure demand accelerates. Here is a timely look at the case for ...
As the CLARITY Act advances, these crypto tokens could see renewed investor interest. Grayscale highlights revenue-ge...
The BIS warns that stablecoins becoming central bank policy questions are moving from crypto markets into sovereign d...
SpaceX is expanding beyond rockets with a bold $60B Cursor deal. This strategic shift could redefine how investors va...
Apple is reportedly exploring a memory supplier in China to ease a chip shortage. Industry skeptics say the pivot won...
A pivotal quarter could set the tone for Micron in 2026. This guide breaks down what happened, why it happened, and h...
Dell Technologies rides a surge in AI infrastructure demand, with a raised outlook and a growing AI backlog lifting t...
An uncalled paving crew showed up to a Lexington home, quoting a tempting price that ballooned into a $78k bill. This...